Salomon O, Steinberg D M, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U
Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel-Hashomer, Israel.
Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):511-8. doi: 10.1161/01.atv.19.3.511.
The inherited thrombophilias--deficiencies of protein C, protein S, and antithrombin III--and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE). The aim of this study was to determine the prevalence of single and combined prothrombotic factors in patients with idiopathic VTE and to estimate the associated risks. The study group consisted of 162 patients referred for work-up of thrombophilia after documented VTE. The controls were 336 consecutively admitted patients. In all subjects factor V G1691A, factor II G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T were analyzed by specific polymerase chain reactions and restriction enzymes. Activities of antithrombin III and protein C, free protein S antigen, and lupus anticoagulant were determined in a subset of 109 patients who were not receiving oral anticoagulants. The prevalences of heterozygotes and homozygotes for factor V G1691A and factor II G20210A among patients and controls were 40.1% versus 3.9% and 18.5% versus 5.4%, respectively (P=0.0001). The prevalence of homozygotes for MTHFR C677T in patients was 22.8% and in controls, 14.3% (P=0.025). Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively. Two or more polymorphisms were detected in 27 of 162 patients (16.7%) and in 3 of 336 controls (0.9%). Logistic regression analysis disclosed odds ratios of 58.6 (confidence interval [CI], 22.1 to 155.2) for joint occurrence of factor V and factor II polymorphisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II and MTHFR polymorphisms. Among 109 patients in whom a complete thrombophilic work-up was performed, 74% had at least 1 underlying defect. These data indicate that in most patients referred for evaluation of thrombophilia due to idiopathic VTE, 1 or more underlying genetic predispositions were discernible. The presence of >1 of the prothrombotic polymorphisms was associated with a substantial risk of VTE.
遗传性血栓形成倾向——蛋白C、蛋白S和抗凝血酶III缺乏——以及血栓前多态性因子V G1691A和因子II G20210A使患者易患静脉血栓栓塞(VTE)。本研究的目的是确定特发性VTE患者中单一和联合血栓前因子的患病率,并评估相关风险。研究组由162例在记录有VTE后转诊进行血栓形成倾向检查的患者组成。对照组为336例连续入院的患者。对所有受试者通过特异性聚合酶链反应和限制性内切酶分析因子V G1691A、因子II G20210A和亚甲基四氢叶酸还原酶(MTHFR)C677T。在109例未接受口服抗凝剂治疗的患者亚组中测定了抗凝血酶III和蛋白C的活性、游离蛋白S抗原和狼疮抗凝物。患者和对照组中因子V G1691A和因子II G20210A杂合子和纯合子的患病率分别为40.1%对3.9%和18.5%对5.4%(P = 0.0001)。患者中MTHFR C677T纯合子的患病率为22.8%,对照组为14.3%(P = 0.025)。发现杂合子和纯合子因子V G1691A、因子II G20210A以及纯合子MTHFR C677T是VTE的独立危险因素,比值比分别为16.3、3.6和2.1。162例患者中有27例(16.7%)检测到两种或更多种多态性,336例对照组中有3例(0.9%)检测到。逻辑回归分析显示,因子V和因子II多态性联合出现的比值比为58.6(置信区间[CI],22.1至155.2),因子V和MTHFR多态性联合出现的比值比为35.0(CI,14.5至84.7),因子II和MTHFR多态性联合出现的比值比为7.7(CI,3.0至19.6)。在进行了全面血栓形成倾向检查的109例患者中,74%至少有一种潜在缺陷。这些数据表明,在大多数因特发性VTE转诊进行血栓形成倾向评估的患者中,可以识别出一种或多种潜在的遗传易感性。存在一种以上血栓前多态性与VTE的高风险相关。